Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Availability depends on regulatory review, approximately 10 to 12 months for FDA review, and production scale-up post-approval
Tirzepatide's GIP/GLP-1 dual agonism harnesses two complementary incretin pathways for potent glucose lowering and appetite suppression, and its FDA approval, extensive Phase 3 evidence, and growing real-world experience make it the established standard for obesity and type 2 diabetes treatment
Through those, you could pay between $349 and $499 per month for Zepbounds vial and syringe and $499 a month for Wegovy in the auto-injector pen
Pharma giant Eli Lilly also is pushing to get FDA approval for tirzepatide, a diabetes medication, to be added to the weight loss market in the U.S
Ro's pricing is more layered
The real benefits arent about inches
US$ 25.87
US$ 27.68
US$ 27.33
US$ 25.54
US$ 23.89
US$ 28.03
US$ 27.76
US$ 29.83
US$ 20.53
US$ 25.03
